# Hyperkalemic effect of drug–drug interaction between esaxerenone and trimethoprim in patients with hypertension: a pilot study

**Authors:** Toshinori Hirai, Shun Ueda, Toru Ogura, Kan Katayama, Kaoru Dohi, Yuki Kondo, Yuka Sakazaki, Yoichi Ishitsuka, Takuya Iwamoto

PMC · DOI: 10.1186/s40780-024-00366-6 · Journal of Pharmaceutical Health Care and Sciences · 2024-08-02

## TL;DR

This study found that combining esaxerenone and trimethoprim does not significantly increase potassium levels beyond what esaxerenone alone causes, but the effect is linked to kidney function and trimethoprim dosage.

## Contribution

The study provides new evidence on the hyperkalemic drug–drug interaction between esaxerenone and trimethoprim in hypertensive patients.

## Key findings

- Serum potassium levels increased significantly with both esaxerenone alone and in combination with trimethoprim.
- ΔK correlated strongly with changes in blood urea nitrogen and serum creatinine, indicating a link to renal function.
- There was a non-significant trend between ΔK and trimethoprim cumulative weekly dose.

## Abstract

We examined whether the pharmacodynamic drug–drug interaction between esaxerenone and trimethoprim enhances the hyperkalemic effect.

A retrospective observational study was conducted to identify patients >18 years undertaking esaxerenone alone or esaxerenone plus trimethoprim at Mie University Hospital from May 2019 to December 2022. We performed propensity score-matching (1:1) to compare between-group differences in the maximum change in serum potassium levels (ΔK) using the Mann–Whitney U test. For esaxerenone plus trimethoprim, Spearman's correlation coefficients were used to examine correlations between ΔK and variables, including changes in blood urea nitrogen (ΔBUN), serum creatinine levels (ΔCr), and weekly trimethoprim cumulative dose.

Out of propensity score-matched groups (n=8 each), serum potassium levels significantly increased after administration of esaxerenone alone (4.4 [4.2 to 4.7] meq/L to 5.2 [4.7 to 5.4] meq/L, p=0.008) and esaxerenone plus trimethoprim (4.2 [4.0 to 5.1] meq/L to 5.4 [4.7 to 5.5] meq/L, p=0.023). ΔK did not significantly differ between the groups (esaxerenone alone; 0.6 [0.3 to 0.9] meq/L vs. esaxerenone plus trimethoprim; 1.0 [0.4 to 1.3] meq/L, p=0.342). ΔK positively correlated with ΔBUN (r=0.988, p<0.001) or ΔCr (r=0.800, p=0.017). There was a trend of correlation of ΔK with a weekly cumulative trimethoprim dose (r=0.607, p=0.110).

The hyperkalemic effect of the drug–drug interaction between esaxerenone and trimethoprim is not notable and related to renal function and trimethoprim dosage.

The online version contains supplementary material available at 10.1186/s40780-024-00366-6.

## Linked entities

- **Chemicals:** esaxerenone (PubChem CID 25052023), trimethoprim (PubChem CID 5578)

## Full-text entities

- **Diseases:** Hyperkalemic (OMIM:614495), hypertension (MESH:D006973)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11295366/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11295366/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC11295366/full.md

---
Source: https://tomesphere.com/paper/PMC11295366